Cepharanthine - Sairiyo Therapeutics
Alternative Names: PD-001 - Sairiyo Therapeutics; PD001Latest Information Update: 26 Aug 2024
At a glance
- Originator Sairiyo Therapeutics
- Developer PharmaTher; Sairiyo Therapeutics
- Class Alkaloids; Anti-infectives; Anti-inflammatories; Antineoplastics; Antivirals; Nonsteroidal anti-inflammatories
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer; Infections; Monkeypox
Most Recent Events
- 26 Aug 2024 Preclinical trials in Monkeypox in Canada (PO)
- 19 Aug 2024 Australian Human Research Ethics Committee approves CTA for Cepharanthine in cancer
- 19 Aug 2024 Sairiyo announces intention to file IND application for PD 001 to the US FDA to initiate phase II and phase II clinical trials in the USA .